ESMO WCGIC 2020 | SWOG S1310: trametinib vs 5-FU/capecitabine in refractory advanced biliary cancer

Richard D. Kim • 2 Jul 2020

ESMO WCGIC 2020

Bile Duct Cancer Gastrointestinal Cancer 5-fluorouracil Antibodies Capecitabine Trametinib

Richard Kim, MD, Moffitt Cancer Center, Tampa, FL, outlines results from a Phase II trial evaluating single agent MEK inhibitor trametinib versus 5-fluorouracil (5-FU) or capecitabine in refractory advanced biliary cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Nivolumab for CCA

Richard D. Kim • 3 Jul 2020

HIMALAYA: tremelimumab + durvalumab in unresectable HCC

Richard D. Kim • 27 Jan 2022

Immunotherapy plus TKIs for the treatment of CRC

Richard D. Kim • 27 Jan 2022

TOPAZ-1: the addition of durvalumab to chemotherpay for the treatment of BTC in the 1st-line setting

Richard D. Kim • 27 Jan 2022

Related Videos

Regorafenib in refractory biliary tract cancer

Richard D. Kim • 3 Jul 2020

COVID-19 & the management of cancer patients

Alberto F. Sobrero • 3 Jun 2020

HER-2 conversion: a phenomenon in trastuzumab resistance

Russell Petty • 5 Nov 2019

The gut microbiome: role in causing and detecting colorectal cancer

Paul O'Toole • 29 Nov 2018